My Clinical Approach to Renal Oncocytoma
Oncocytoma is one of the most common benign kidney tumours — yet one of the most challenging to manage. The problem is not the tumour itself, but the inability to reliably distinguish it from chromophobe renal cell carcinoma on imaging alone. This uncertainty often leads to surgical removal that would be unnecessary if complete diagnostic certainty were available beforehand.
Renal mass biopsy has significantly improved management — allowing selected patients with confirmed oncocytoma to avoid surgery. However, differentiation from chromophobe RCC on biopsy is not always unequivocal — even with immunohistochemistry.
My individualised approach:
- Renal mass biopsy in patients eligible for active surveillance — to avoid unnecessary surgery.
- Partial nephrectomy in young, healthy patients where malignancy cannot be excluded.
- Active surveillance in biopsy-confirmed oncocytoma <4 cm with high surgical risk.
- Genetic testing in patients with multiple or bilateral oncocytomas (BHD, oncocytosis).
What is Renal Oncocytoma
Renal oncocytoma is a benign epithelial kidney tumour arising from the intercalated cells of the collecting duct. It is composed of oncocytes — large cells with eosinophilic cytoplasm due to mitochondrial accumulation.
It represents ~5–7% of all renal neoplasms and is the second most common benign solid kidney tumour after angiomyolipoma. Unlike other benign renal tumours, its management is more complex due to its imaging similarity to chromophobe renal cell carcinoma (RCC).
A characteristic imaging finding is the central stellate scar ("spoke-wheel pattern") on CT or MRI — but this appears in only ~33% of cases and is not pathognomonic.
Oncocytoma vs Chromophobe RCC
Both arise from the collecting duct and share histological features. Differentiation requires immunohistochemistry (CK7, CD117) or electron microscopy. Until histologically confirmed, every solid renal mass is treated as potentially malignant.
Epidemiology & Risk Factors
Oncocytoma predominantly affects adults aged 60–70 years with a male-to-female ratio of ~2:1. It is almost always discovered incidentally on imaging for another reason.
Sporadic (majority)
Solitary, unilateral oncocytoma with no family history. The vast majority of oncocytomas belong to this category.
Birt-Hogg-Dubé Syndrome (BHD)
Rare autosomal dominant syndrome (FLCN mutations) with multiple oncocytomas or hybrid oncocytic/chromophobe neoplasms, skin lesions (fibrofolliculomas), and risk of pneumothorax.
Renal Oncocytosis
Rare condition with multiple bilateral oncocytomas — may be associated with BHD or appear sporadically.
Co-existence with RCC
In 13–32% of cases, oncocytoma coexists with renal cell carcinoma in the same or contralateral kidney — making comprehensive evaluation of both kidneys mandatory.
Symptoms & Clinical Presentation
Oncocytoma is in the majority of cases asymptomatic and discovered incidentally. Larger oncocytomas may present with:
Dull Flank / Loin Pain
In larger oncocytomas (>5 cm), the growing mass may cause a sense of heaviness or dull ache in the renal area.
Haematuria
A rare presentation. Macroscopic haematuria always requires complete urological evaluation to exclude a malignant cause. See: haematuria.
Incidental Finding (Majority)
>80% of oncocytomas are discovered as incidentalomas on ultrasound or CT performed for another reason (e.g. abdominal pain, urolithiasis, cardiovascular screening).
Every Renal Mass is Treated as Malignant Until Proven Otherwise
Oncocytoma cannot be reliably distinguished from renal cell carcinoma on imaging alone. This means:
- Every new renal mass requires prompt urological evaluation.
- Watchful waiting without diagnosis increases the risk of delayed RCC treatment.
- Renal mass biopsy is a safe, reliable examination that can prevent unnecessary surgery.
Diagnosis & Imaging Evaluation
Diagnosis is based on a combination of imaging and — for definitive confirmation — histology:
Triphasic CT Scan
Primary evaluation tool. Characteristic oncocytoma features: homogeneous mass, central stellate scar ("spoke-wheel", ~33%), avid enhancement. Cannot exclude chromophobe RCC.
MRI
Better characterisation of indeterminate masses. The central scar appears hypointense on T2 — but is not pathognomonic.
Renal Mass Biopsy
Investigation of choice for definitive diagnosis in patients considering active surveillance. Accuracy ~80–90% for oncocytoma. In ~10% it cannot differentiate from chromophobe RCC.
Renal Ultrasound
Useful for initial detection but insufficient for characterisation. Every solid renal mass found on ultrasound requires CT or MRI.
Histological Diagnostic Criteria
Oncocytes in nested or tubular architecture, eosinophilic cytoplasm, central round nucleus
CK7 focal/negative, CD117 positive — in contrast to chromophobe RCC (CK7 diffuse positivity)
Abundant mitochondria filling the cytoplasm — pathognomonic finding
Oncocytoma: loss of chromosomes 1, 14 or Y. Chromophobe RCC: multiple monosomies (1, 2, 6, 10, 13, 17, 21)
BHD Syndrome & Oncocytosis
In certain cases, oncocytoma is part of broader clinical syndromes:
Birt-Hogg-Dubé Syndrome (BHD)
Autosomal dominant syndrome due to inactivation of the FLCN (folliculin) gene. Clinical picture: multiple renal neoplasms (oncocytomas, hybrid oncocytic/chromophobe, clear cell RCC), cutaneous fibrofolliculomas and trichodiscomas, increased pneumothorax risk. Requires genetic testing and MRI surveillance every 3 years.
Renal Oncocytosis
Rare condition with diffuse bilateral oncocytomas and micro-oncocytomas. Complete surgical removal is impractical — management focuses on preserving renal function (resection only for suspicious lesions).
Hybrid Oncocytic/Chromophobe Neoplasm
An intermediate tumour type sharing features of oncocytoma and chromophobe RCC. Mainly associated with BHD. Generally benign biological behaviour but requires surveillance.
Treatment Options
Treatment choice depends primarily on the level of diagnostic certainty, tumour size, patient age, and comorbidities:
Active Surveillance — Biopsy-Confirmed Oncocytoma
Acceptable option in biopsy-confirmed oncocytoma <4 cm, high surgical risk, or age >70 years. MRI or CT every 12 months — surgery if size >4 cm or rapid growth (>0.5 cm/year).
Partial Nephrectomy — Selective Choice
In young, healthy patients where biopsy is indeterminate or chromophobe RCC cannot be excluded. Laparoscopic or robotic approach preferred to preserve renal function. See: partial nephrectomy.
Renal Mass Biopsy — Before Any Decision
In patients eligible for active surveillance, pre-decision biopsy can prevent unnecessary surgery in confirmed oncocytoma. Performed under CT or ultrasound guidance — safe with a low complication rate.
Surgical Management
When surgical treatment is deemed necessary, the approach aims to preserve renal function:
Robotic / Laparoscopic Partial Nephrectomy
Treatment of choice for most oncocytomas requiring surgery. Tumour excision with negative surgical margins while preserving functional renal parenchyma.
Open Partial Nephrectomy
In complex anatomical locations (endophytic, hilar tumours) or large oncocytomas >7 cm where minimally invasive approach is technically challenging.
Thermal Ablation
Cryoablation or radiofrequency ablation in small oncocytomas (<4 cm) in patients with high surgical risk or solitary kidney. Lower complete necrosis rate compared to surgery.
Radical Nephrectomy — Rare Indication
Only in very large oncocytomas displacing the entire kidney or when partial excision is technically unfeasible. Avoided whenever possible to preserve renal function.
Follow-up & Prognosis
Follow-up depends on whether the patient underwent surgical removal or is on active surveillance:
- After surgical removal of confirmed oncocytoma: CT/MRI at 12 months — then every 2–3 years for 10 years.
- Active surveillance: MRI or CT every 12 months — surgery if growth >0.5 cm/year or new imaging findings.
- BHD syndrome: renal MRI every 3 years — starting at age 18 or 5 years before the earliest family manifestation.
- Oncocytosis: annual MRI and nephrology assessment of renal function.
- Oncocytoma/RCC co-existence: follow-up per RCC protocol (CT/MRI every 6 months for the first 3 years).
Prognosis
Confirmed oncocytoma has an excellent prognosis — it does not become cancer and does not metastasise. The only risk is a delayed diagnosis of chromophobe RCC initially mistaken for oncocytoma. This is why precise histological diagnosis remains critical even for this so-called “benign” renal mass.
Frequently Asked Questions (FAQ)
Is renal oncocytoma cancer?
No. Renal oncocytoma is a benign kidney tumour composed of oncocytes — large cells with mitochondria-rich eosinophilic cytoplasm. It does not metastasise and does not progress to cancer. The main challenge is that it cannot be reliably distinguished from chromophobe renal cell carcinoma on imaging alone — which often leads to biopsy or surgical removal.
How is oncocytoma diagnosed?
Imaging diagnosis is reliable only in classic cases (central "spoke-wheel" scar on CT/MRI). In most cases, renal mass biopsy is required for histological confirmation and differentiation from chromophobe RCC. Definitive diagnosis is based on histopathology.
Does oncocytoma require surgery?
Not always. In patients with biopsy-confirmed oncocytoma, active surveillance is an acceptable option — particularly for small (<4 cm) asymptomatic findings in elderly patients or those with significant comorbidities. Surgical removal is preferred when malignancy cannot be excluded or in young, healthy patients.
What is Birt-Hogg-Dubé syndrome?
It is a rare autosomal dominant syndrome (FLCN/folliculin mutations) associated with hybrid oncocytic/chromophobe renal neoplasms, oncocytomas, skin fibrofolliculomas, and spontaneous pneumothorax. Genetic testing is recommended in patients with multiple oncocytomas.
What is renal oncocytosis?
Oncocytosis is a rare condition with multiple oncocytomas in one or both kidneys — often alongside hybrid oncocytic/chromophobe tumours. Management is challenging due to the inability to completely remove all lesions while preserving renal function.
Can oncocytoma metastasise?
Classic oncocytoma is considered benign and does not metastasise. Rarely, cases with unusual histological features may represent a misdiagnosed chromophobe RCC. This is why precise histological diagnosis is critical.
How common is renal oncocytoma?
It represents approximately 5–7% of all renal neoplasms. It occurs predominantly in men aged 60–70 and is usually discovered incidentally on imaging performed for another reason. It may coexist with renal cell carcinoma in the same kidney (~13–32% of cases) — making comprehensive evaluation essential.
What is the difference between oncocytoma and chromophobe RCC?
Both arise from the collecting duct, share oncocytic cell features, and may look similar on imaging. Oncocytoma is benign, whereas chromophobe RCC has potentially malignant behaviour. Definitive differentiation requires immunohistochemistry and electron microscopy on the surgical specimen.
Related Topics
Book Your Appointment in Rhodes
Incidental renal mass finding? Prompt urological evaluation determines whether biopsy, surgery, or active surveillance is the right approach.
References – Sources
- EAU Guidelines on Renal Cell Carcinoma 2024 — uroweb.org
- Moch H, et al. WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. IARC 2016.
- Hsieh JJ, et al. Renal cell carcinoma. Nat Rev Dis Primers 2017;3:17009.
- Pavlovich CP, et al. Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol 2005;173:1482.
- Siegel RL, et al. Cancer statistics 2024. CA Cancer J Clin 2024.
Medical Review
Dr. Marinos Vasilas, Urologist – Andrologist
Dr. Marinos Vasilas runs a private urology practice in Rhodes with expertise in renal mass management, benign kidney tumours, and laparoscopic/robotic nephrectomy. He follows the EAU Guidelines 2024.
View full profile
